CanSino Biologics: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
== CanSino Biologics == | |||
[[File:CanSino_Convidecia.jpg|thumb|right|200px|CanSino's Convidecia COVID-19 vaccine]] | |||
CanSino Biologics | '''CanSino Biologics Inc.''' is a Chinese biopharmaceutical company that specializes in the research, development, manufacturing, and commercialization of vaccine products for human use. The company is known for its innovative approach to vaccine development and has gained international recognition for its work on the [[COVID-19 pandemic]]. | ||
== | === History === | ||
CanSino Biologics was founded in 2009 in [[Tianjin]], [[China]]. The company was established by a group of scientists with extensive experience in the vaccine industry, aiming to develop high-quality vaccines for the global market. Since its inception, CanSino has focused on developing vaccines for infectious diseases, including [[tuberculosis]], [[meningitis]], and [[Ebola virus disease]]. | |||
=== COVID-19 Vaccine Development === | |||
During the [[COVID-19 pandemic]], CanSino Biologics developed a COVID-19 vaccine known as '''Convidecia'''. This vaccine is based on a recombinant adenovirus type-5 vector (Ad5) and was one of the first COVID-19 vaccines to be approved for emergency use in China. Convidecia is administered as a single-dose vaccine, which differentiates it from many other COVID-19 vaccines that require two doses. | |||
=== Technology and Innovation === | |||
CanSino Biologics utilizes advanced technologies in its vaccine development processes. The company employs recombinant DNA technology and viral vector platforms to create effective and safe vaccines. The use of adenovirus vectors, such as in the Convidecia vaccine, allows for the delivery of genetic material into host cells, prompting an immune response without causing disease. | |||
== | === Global Impact === | ||
CanSino's Convidecia vaccine has been distributed to several countries around the world, contributing to the global effort to combat the COVID-19 pandemic. The vaccine's single-dose regimen and ease of storage and transportation have made it an attractive option for many countries, particularly those with limited healthcare infrastructure. | |||
CanSino | |||
== Related Pages == | |||
* [[COVID-19 pandemic]] | |||
* [[Vaccine]] | |||
* [[Adenovirus]] | |||
* [[Biopharmaceutical]] | * [[Biopharmaceutical]] | ||
[[Category:Biopharmaceutical companies]] | [[Category:Biopharmaceutical companies]] | ||
[[Category:COVID-19 vaccines]] | |||
[[Category:Companies established in 2009]] | |||
[[Category:Companies based in Tianjin]] | [[Category:Companies based in Tianjin]] | ||
<gallery> | |||
File:CanSino_Biologics_logo.svg|Logo of CanSino Biologics | |||
File:CanSino_Convidecia.jpg|CanSino Convidecia vaccine | |||
File:Lox-and-smoked-whitefish-01.jpg|Lox and smoked whitefish | |||
</gallery> | |||
Latest revision as of 00:57, 18 February 2025
CanSino Biologics[edit]
CanSino Biologics Inc. is a Chinese biopharmaceutical company that specializes in the research, development, manufacturing, and commercialization of vaccine products for human use. The company is known for its innovative approach to vaccine development and has gained international recognition for its work on the COVID-19 pandemic.
History[edit]
CanSino Biologics was founded in 2009 in Tianjin, China. The company was established by a group of scientists with extensive experience in the vaccine industry, aiming to develop high-quality vaccines for the global market. Since its inception, CanSino has focused on developing vaccines for infectious diseases, including tuberculosis, meningitis, and Ebola virus disease.
COVID-19 Vaccine Development[edit]
During the COVID-19 pandemic, CanSino Biologics developed a COVID-19 vaccine known as Convidecia. This vaccine is based on a recombinant adenovirus type-5 vector (Ad5) and was one of the first COVID-19 vaccines to be approved for emergency use in China. Convidecia is administered as a single-dose vaccine, which differentiates it from many other COVID-19 vaccines that require two doses.
Technology and Innovation[edit]
CanSino Biologics utilizes advanced technologies in its vaccine development processes. The company employs recombinant DNA technology and viral vector platforms to create effective and safe vaccines. The use of adenovirus vectors, such as in the Convidecia vaccine, allows for the delivery of genetic material into host cells, prompting an immune response without causing disease.
Global Impact[edit]
CanSino's Convidecia vaccine has been distributed to several countries around the world, contributing to the global effort to combat the COVID-19 pandemic. The vaccine's single-dose regimen and ease of storage and transportation have made it an attractive option for many countries, particularly those with limited healthcare infrastructure.
Related Pages[edit]
-
Logo of CanSino Biologics -
CanSino Convidecia vaccine -
Lox and smoked whitefish
